Literature DB >> 25550546

CD47 activation-induced UHRF1 over-expression is associated with silencing of tumor suppressor gene p16INK4A in glioblastoma cells.

Abdelaziz Boukhari1, Mahmoud Alhosin1, Christian Bronner2, Krizia Sagini1, Cécile Truchot1, Emilie Sick1, Valerie B Schini-Kerth1, Philippe André1, Yves Mély1, Marc Mousli1, Jean-Pierre Gies3.   

Abstract

CD47, an integrin-associated protein is over-expressed in several tumors including glioblastomas. Activation of CD47 induces proliferation of human astrocytoma cells but not normal astrocytes via an Akt-dependent way. However, the pathways mediating this process are still unknown. The epigenetic integrator UHRF1 (Ubiquitin-like containing PHD and RING Finger 1) is over-expressed in various cancers and plays a vital role in the silencing of numerous tumor suppressor genes including p16(INK4A), thereby promoting cell proliferation. The aim of the present study was to investigate the role of UHRF1 and p16(INK4A) in CD47-induced effects. Herein we showed that activation of CD47 in human astrocytoma cell lines U87 and CCF- STTG1 (Grade IV), up-regulated the expression of UHRF1 with subsequent down-regulation of p16(INK4A), thus promoting cell proliferation. Blockage of CD47 using a blocking antibody down-regulated UHRF1 expression, accompanied by a re-expression of p16(INK4A), conducting to decreased cell proliferation in both cancer cell lines. Neither CD47 activation nor its blocking has any effect on UHRF1/p16(INK4A) expression in normal human astrocytes. Depletion of CD47 in the U87 cell line resulted in down-regulation of UHRF1. We also found that CD47 activated the inflammatory genes IL-6, IL-7 and MCP-1 by a NF-κB-dependent mechanism in human astrocytoma but not in normal astrocytes. In conclusion, the present findings indicate that CD47 activation increases expression of UHRF1 and suggest, for the first time, that CD47 regulates the epigenetic code by targeting UHRF1. This could represent a new pathway towards cell proliferation and metastasis. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Astrocytoma; CD47; NF-κB; UHRF1

Mesh:

Substances:

Year:  2015        PMID: 25550546

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  25 in total

Review 1.  Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling.

Authors:  Sukhbir Kaur; David D Roberts
Journal:  Int J Biochem Cell Biol       Date:  2016-05-06       Impact factor: 5.085

Review 2.  A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.

Authors:  Craig L Parfett; Daniel Desaulniers
Journal:  Int J Mol Sci       Date:  2017-06-01       Impact factor: 5.923

3.  Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer.

Authors:  David D Roberts; Sukhbir Kaur; David R Soto-Pantoja
Journal:  J Cell Commun Signal       Date:  2015-03-18       Impact factor: 5.782

4.  CD47 (Cluster of Differentiation 47).

Authors:  Sukhbir Kaur; Jeffrey S Isenberg; David D Roberts
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2021

Review 5.  Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Authors:  Michael E Salacz; Richard E Kast; Najmaldin Saki; Ansgar Brüning; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

Review 6.  Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer.

Authors:  Mahmoud Alhosin; Ziad Omran; Mazin A Zamzami; Abdulrahman L Al-Malki; Hani Choudhry; Marc Mousli; Christian Bronner
Journal:  J Exp Clin Cancer Res       Date:  2016-11-14

7.  Targeting microRNA/UHRF1 pathways as a novel strategy for cancer therapy.

Authors:  Hani Choudhry; Mazin A Zamzami; Ziad Omran; Wei Wu; Marc Mousli; Christian Bronner; Mahmoud Alhosin
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

8.  Targeting NF-κB with Nanotherapy in a Mouse Model of Adult T-Cell Leukemia/Lymphoma.

Authors:  Daniel A Rauch; John C Harding; Lee Ratner; Samuel A Wickline; Hua Pan
Journal:  Nanomaterials (Basel)       Date:  2021-06-16       Impact factor: 5.076

9.  Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.

Authors:  Michael Zhang; Gregor Hutter; Suzana A Kahn; Tej D Azad; Sharareh Gholamin; Chelsea Y Xu; Jie Liu; Achal S Achrol; Chase Richard; Pia Sommerkamp; Matthew Kenneth Schoen; Melissa N McCracken; Ravi Majeti; Irving Weissman; Siddhartha S Mitra; Samuel H Cheshier
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

Review 10.  The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?

Authors:  Zahra Beizavi; Seyed Mohammad Gheibihayat; Hadis Moghadasian; Hossein Zare; Babak Shirazi Yeganeh; Hassan Askari; Sina Vakili; Amir Tajbakhsh; Amir Savardashtaki
Journal:  Mol Biol Rep       Date:  2021-07-17       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.